Ordered Mesoporous Silica Delivering siRNA as Cancer Nanotherapeutics: A Comprehensive Review
- PMID: 38606473
- DOI: 10.1021/acsbiomaterials.3c01749
Ordered Mesoporous Silica Delivering siRNA as Cancer Nanotherapeutics: A Comprehensive Review
Abstract
Nanosized mesoporous silica has emerged as a promising flexible platform delivering siRNA for cancer treatment. This ordered mesoporous nanosized silica provides attractive features of well-defined and tunable porosity, structure, high payload, and multiple functionalizations for targeted delivery and increasing biocompatibility over other polymeric nanocarriers. Moreover, it also overcomes the lacunae associated with traditional administration of drugs. Chemically modified porous silica matrix efficiently entraps siRNA molecules and prevents their enzymatic degradation and premature release. This Review discusses the synthesis of silica using the sol-gel approach and the advantages with different silica mesostructure. Herein, the factors affecting the synthesis of silica at nanometer scale, shape, porosity and nanoparticle surface modification are also highlighted to attain the desired nanostructured silica carriers. Additional emphasis is given to chemically modified silica delivering siRNA, where the silica nanoparticle surface was modified with different chemical moieties such as amine modified with (3-aminoropyl) triethoxysilane, polyethylenimine, chitosan, poly(ethylene glycol), and cyclodextrin polymer modification to attain high therapeutic loading, improved dispersibility and biocompatibility. Upon systemic administration, ordered mesoporous nanosized silica encounters blood cells, immune cells, and organs mainly of the reticuloendothelial system (RES). Thereby, biocompatibility and biodistribution of silica based nanocarriers are deliberated to design principles for smart and efficacious nanostructured silica-siRNA carriers and their clinical trial status. This Review further reports the future scopes and challenges for developing silica nanomaterial as a promising siRNA delivery vehicle demanding FDA approval.
Keywords: ordered mesoporous structures; polymers; siRNA mediated gene silencing; silica nanoparticles; sol−gel silica.
Similar articles
-
Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.Antioxid Redox Signal. 2014 Aug 10;21(5):707-22. doi: 10.1089/ars.2012.5076. Epub 2013 Sep 28. Antioxid Redox Signal. 2014. PMID: 23931896
-
Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.Curr Drug Deliv. 2016;13(7):1176-1182. doi: 10.2174/1567201813666151231094056. Curr Drug Deliv. 2016. PMID: 26718488
-
Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility.Acc Chem Res. 2013 Mar 19;46(3):792-801. doi: 10.1021/ar3000986. Epub 2013 Feb 6. Acc Chem Res. 2013. PMID: 23387478 Free PMC article.
-
Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers.Nanoscale. 2017 Oct 19;9(40):15252-15277. doi: 10.1039/c7nr05762h. Nanoscale. 2017. PMID: 28984885 Review.
-
Chemoresponsive smart mesoporous silica systems - An emerging paradigm for cancer therapy.Int J Pharm. 2018 Dec 20;553(1-2):310-326. doi: 10.1016/j.ijpharm.2018.10.026. Epub 2018 Oct 10. Int J Pharm. 2018. PMID: 30316004 Review.
Cited by
-
Applications of Tailored Mesoporous Silicate Nanomaterials in Regenerative Medicine and Theranostics.Int J Mol Sci. 2025 Aug 16;26(16):7918. doi: 10.3390/ijms26167918. Int J Mol Sci. 2025. PMID: 40869241 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical